Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect
News and Views Disease Lists/Categories
About
About MalaCards Datasets Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MCID: DST006
MIFTS: 45

Diastolic Heart Failure

Categories: Cardiovascular diseases
Genes Tissues Related diseases Publications Pathways Drugs
Sources

Aliases & Classifications for Diastolic Heart Failure

About this section

MalaCards integrated aliases for Diastolic Heart Failure:

Name: Diastolic Heart Failure 12 15 17
Heart Failure, Diastolic 44 70

Classifications:

MalaCards categories:
Anatomical: Cardiovascular diseases
See all MalaCards categories (disease lists)


External Ids:

Disease Ontology 12 DOID:9775
ICD9CM 34 428.3
MeSH 44 D054144
SNOMED-CT 67 418304008
ICD10 32 I50.30
UMLS 70 C1135196
Sources

Summaries for Diastolic Heart Failure

About this section
MalaCards based summary : Diastolic Heart Failure, also known as heart failure, diastolic, is related to idiopathic edema and atrial standstill 1. An important gene associated with Diastolic Heart Failure is ACE (Angiotensin I Converting Enzyme), and among its related pathways/superpathways are Respiratory electron transport, ATP synthesis by chemiosmotic coupling, and heat production by uncoupling proteins. and p70S6K Signaling. The drugs Empagliflozin and Angiotensin II have been mentioned in the context of this disorder. Affiliated tissues include heart, kidney and endothelial, and related phenotypes are cardiovascular system and homeostasis/metabolism

Sources

Related Diseases for Diastolic Heart Failure

About this section

Diseases related to Diastolic Heart Failure via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 277)
# Related Disease Score Top Affiliating Genes
1 idiopathic edema 30.8 NPPB NPPA ACE
2 atrial standstill 1 30.6 TTN NPPB MYBPC3 ACE
3 systolic heart failure 30.5 TTN NPPB NPPA NOS3 MMP9 MMP2
4 pulmonary edema 30.5 REN NPPB NPPA NOS3 AGTR1 ACE
5 restrictive cardiomyopathy 30.5 TTN NPPB MYBPC3 ACE
6 hypertension, diastolic 30.3 REN ACE
7 rheumatic heart disease 30.2 TGFB1 NPPB ACE
8 constrictive pericarditis 30.2 TTN REN NPPB ACE
9 atherosclerosis susceptibility 30.1 NOS3 MMP9 AGTR1 ACE
10 sleep apnea 30.1 REN NPPB NOS3 AGT ACE
11 left bundle branch hemiblock 30.1 REN NPPB ACE
12 cardiac tamponade 30.1 REN NPPB ACE
13 arteriosclerosis 30.0 NOS3 MMP9 CST3 ACE
14 patent ductus arteriosus 1 30.0 REN NPPB ACE
15 acute kidney failure 29.9 REN NPPA CST3
16 eclampsia 29.9 REN NOS3 AGT ACE
17 heart valve disease 29.9 TGFB1 REN NPPB NPPA MIR499A ACE
18 mitral valve insufficiency 29.9 TTN REN NPPB NPPA MYBPC3 ACE
19 congestive heart failure 29.9 TTN REN PDE5A NPPB NPPA NOS3
20 respiratory failure 29.8 TTN REN NPPB NPPA ACE
21 atrial fibrillation 29.8 TTN NPPB NPPA MYBPC3 AGTR1 AGT
22 arteries, anomalies of 29.8 REN NOS3 MIR499A AGTR1 ACE
23 central sleep apnea 29.7 REN NPPB NPPA NOS3 ACE
24 pulmonary hypertension 29.7 REN PDE5A NPPB NPPA NOS3 AGTR1
25 hypertensive heart disease 29.6 REN NPPB NPPA MMP9 MMP2 MMP1
26 cardiac arrest 29.5 TTN REN NPPB MYBPC3 ACE
27 aortic valve disease 1 29.4 REN NOS3 MMP9 MMP2 AGTR1 ACE
28 tricuspid valve insufficiency 29.4 REN PDE5A NPPB ACE
29 renal hypertension 29.4 REN NPPB NOS3 CYBB AGTR1 AGT
30 end stage renal disease 29.3 TGFB1 REN NPPB NOS3 CST3 AGTR1
31 aortic valve disease 2 29.2 TTN REN NPPB NPPA MYBPC3 AGT
32 mitral valve disease 29.2 REN NPPB NPPA NOS3 MMP1 AGTR1
33 autosomal dominant polycystic kidney disease 29.1 TGFB1 REN NPPA NOS3 CST3 AGTR1
34 vascular disease 29.0 TGFB1 REN NPPB NOS3 MMP9 CYBB
35 kidney disease 29.0 TGFB1 REN NPPB NPPA NOS3 CST3
36 chronic kidney disease 28.7 TGFB1 REN NPPB NPPA NOS3 MMP9
37 polycystic kidney disease 28.6 TGFB1 REN NOS3 MMP9 MMP1 CST3
38 pre-eclampsia 28.5 REN PDE5A NPPA NOS3 MMP9 CST3
39 cardiovascular system disease 28.2 REN PDE5A NPPB NPPA NOS3 MIR499A
40 hypertrophic cardiomyopathy 27.8 TTN TGFB1 REN NPPB NPPA NOS3
41 dilated cardiomyopathy 27.6 TTN TGFB1 REN NPPB NPPA NOS3
42 diabetes mellitus 27.5 TGFB1 REN PDE5A NPPB NPPA NOS3
43 lipoprotein quantitative trait locus 27.4 TTN REN PDE5A NPPB NPPA NOS3
44 heart disease 27.2 TTN TGFB1 REN PDE5A NPPB NPPA
45 myocardial infarction 26.9 TGFB1 REN PDE5A NPPB NPPA NOS3
46 arteritic anterior ischemic optic neuropathy 10.4 NOS3 ACE
47 cardiac tuberculosis 10.4 NPPB ACE
48 toxic myocarditis 10.4 NPPB ACE
49 progressive muscular dystrophy 10.4 NPPA CCN2
50 meningococcal infection 10.3 AGTR1 AGT

Graphical network of the top 20 diseases related to Diastolic Heart Failure:



Diseases related to Diastolic Heart Failure
Sources

Symptoms & Phenotypes for Diastolic Heart Failure

About this section

MGI Mouse Phenotypes related to Diastolic Heart Failure:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 10.28 ACE AGT AGTR1 ANKRD1 CCN2 CST3
2 homeostasis/metabolism MP:0005376 10.25 ACE AGT AGTR1 ANKRD1 CCN2 CST3
3 behavior/neurological MP:0005386 10.21 ACE AGT AGTR1 ANKRD1 CYBB MADD
4 growth/size/body region MP:0005378 10.18 ACE AGT AGTR1 ANKRD1 CCN2 CYBB
5 muscle MP:0005369 10.03 AGT ANKRD1 CST3 CYBB MMP2 MMP9
6 nervous system MP:0003631 9.73 ACE AGT AGTR1 CST3 CYBB MADD
7 neoplasm MP:0002006 9.7 ACE CST3 CYBB MMP1 MMP2 MMP9
8 renal/urinary system MP:0005367 9.28 ACE AGT AGTR1 CYBB MMP9 NOS3
Sources

Drugs & Therapeutics for Diastolic Heart Failure

About this section

Drugs for Diastolic Heart Failure (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 121)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Empagliflozin Approved Phase 4 864070-44-0
2
Angiotensin II Approved, Investigational Phase 4 68521-88-0, 4474-91-3, 11128-99-7 172198
3
Valsartan Approved, Investigational Phase 4 137862-53-4 60846
4
Spironolactone Approved Phase 4 1952-01-7, 52-01-7 5833
5
Sodium citrate Approved, Investigational Phase 4 68-04-2
6
Regadenoson Approved, Investigational Phase 4 313348-27-5 219024
7
Adenosine Approved, Investigational Phase 4 58-61-7 60961
8
Dopamine Approved Phase 4 51-61-6, 62-31-7 681
9
Furosemide Approved, Vet_approved Phase 4 54-31-9 3440
10
Metoprolol Approved, Investigational Phase 4 51384-51-1, 37350-58-6 4171
11
Nebivolol Approved, Investigational Phase 4 152520-56-4, 118457-14-0, 99200-09-6 71301
12
Carvedilol Approved, Investigational Phase 4 72956-09-3 2585
13
Acebutolol Approved, Investigational Phase 4 37517-30-9 1978
14
Nadolol Approved Phase 4 42200-33-9 39147
15
Penbutolol Approved, Investigational Phase 4 38363-40-5, 36507-48-9 37464
16
Sotalol Approved Phase 4 959-24-0, 3930-20-9 5253
17
Atenolol Approved Phase 4 29122-68-7 2249
18
Labetalol Approved Phase 4 36894-69-6 3869
19
Propranolol Approved, Investigational Phase 4 525-66-6 4946
20
Bisoprolol Approved Phase 4 66722-44-9 2405
21
Betaxolol Approved, Investigational Phase 4 659-18-7, 63659-18-7 2369
22
Pindolol Approved, Investigational Phase 4 13523-86-9 4828
23
Eplerenone Approved Phase 4 107724-20-9 150310 443872
24
Exenatide Approved, Investigational Phase 4 141758-74-9 15991534
25
Glucagon Approved Phase 4 16941-32-5
26
Citric acid Approved, Nutraceutical, Vet_approved Phase 4 77-92-9 311
27 Mineralocorticoids Phase 4
28 Mineralocorticoid Receptor Antagonists Phase 4
29 diuretics Phase 4
30 Angiotensin II Type 1 Receptor Blockers Phase 4
31 Angiotensin Receptor Antagonists Phase 4
32 Giapreza Phase 4
33 Angiotensinogen Phase 4
34 Phosphodiesterase Inhibitors Phase 4
35 Phosphodiesterase 5 Inhibitors Phase 4
36 Cardiotonic Agents Phase 4
37 Citrate Phase 4
38 Sildenafil Citrate Phase 4 171599-83-0
39 Dopamine Agents Phase 4
40 Sodium Potassium Chloride Symporter Inhibitors Phase 4
41 Antihypertensive Agents Phase 4
42 Antioxidants Phase 4
43 Protective Agents Phase 4
44 Adrenergic beta-Antagonists Phase 4
45 Vasodilator Agents Phase 4
46 calcium channel blockers Phase 4
47 Calcium, Dietary Phase 4
48 Anti-Arrhythmia Agents Phase 4
49 Adrenergic Antagonists Phase 4
50 Adrenergic Agents Phase 4

Interventional clinical trials:

(show top 50) (show all 125)
# Name Status NCT ID Phase Drugs
1 A Phase 4, Single-center, Randomized, Parallel Group Study to Assess Effects of Empagliflozin on Exercise Capacity and Left Ventricular Diastolic Function in Patients With Heart Failure With Preserved Ejection Fraction and Type-2 Diabetes Mellitus Unknown status NCT03753087 Phase 4 Empagliflozin
2 Impacts of Aldosterone Blockade on Myocardial Remodeling in Hypertensive Patients With Diastolic Failing Heart Completed NCT01944384 Phase 4 aldactone
3 Novel Treatment for Diastolic Heart Failure in Women Completed NCT00206232 Phase 4 Spironolactone
4 Aldosterone Antagonism in Diastolic Heart Failure Completed NCT00108251 Phase 4 Eplerenone;Placebo
5 Myocardial Perfusion, Oxidative Metabolism, and Fibrosis in HFpEF Completed NCT02589977 Phase 4 regadenoson
6 SIDAMI - Sildenafil and Diastolic Dysfunction After AMI Completed NCT01046838 Phase 4 Sildenafil;Placebo
7 Randomized Evaluation of Heart Failure With Preserved Ejection Fraction (HFpEF) Patients With Acute Heart Failure and Dopamine (ROPA-DOP) Trial Completed NCT01901809 Phase 4 Furosemide;Dopamine
8 A Double-blind, Randomised, Placebo-controlled, Parallel Group Study to Determine the Effects of Valsartan on Exercise Time in Subjects With Symptomatic Diastolic Heart Failure Completed NCT00171106 Phase 4 valsartan
9 Echocardiographic Assessment of Pulmonary Transit Time Following Exercise Recruiting NCT04336995 Phase 4
10 Improving Treatment Personalization of Pulmonary Hypertension Associated With Diastolic Heart Failure Active, not recruiting NCT02053246 Phase 4 Nebivolol
11 The EMMED-HF Study: Evaluating Metabolic Mechanisms of Ertugliflozin in Diabetes & Heart Failure Not yet recruiting NCT04071626 Phase 4 Ertugliflozin 5 mg;Placebo oral tablet
12 A Phase 4, Randomized, Open Label, Multicenter Prospective Comparative Study To Evaluate The Treatment Of Atrial Fibrillation In Preserved Cardiac Function Heart Failure Not yet recruiting NCT04160000 Phase 4 Rate or Rhythm control antiarrhythmic drugs for atrial fibrillation
13 N-of-1 Trials for Deprescribing Beta-blockers in HFpEF Not yet recruiting NCT04767061 Phase 4 Beta blockers
14 N-of-1 Trials for Deprescribing Beta-blockers in HFpEF Not yet recruiting NCT04757584 Phase 4 Beta blockers
15 Determine the Effectiveness of Eplerenone in Reversing Diastolic Dysfunction, Improving Endothelial Function, and Suppressing Natriuretic Peptides and Collagen Turnover in Patients With Diastolic Heart Failure ( PREDICT Study) Terminated NCT00293150 Phase 4 Eplerenone
16 The Use of Nesiritide in the Management of Acute Diastolic Heart Failure Terminated NCT00083772 Phase 4 Nesiritide
17 Treatment With Glucagon-Like Peptide-1 Receptor, Exenatide, in Patients With Diabetes and Heart Failure With Normal Left Ventricular Ejection Fraction Terminated NCT00799435 Phase 4 Exenatide
18 Udenafil Therapy to Improve Symptomatology, Exercise Tolerance and Hemodynamics in Patients With Heart Failure With Preserved Ejection Fraction: Phase III, Randomized, Double-blind, Placebo-controlled Trial [ULTIMATE-HFpEF Trial] Unknown status NCT01599117 Phase 3 Placebo;Udenafil (Zydena)
19 Sympathetic Renal Denervation in Heart Failure With Normal LV Ejection Fraction: Denervation of the renAl sympathetIc nerveS in hearT Failure With nOrmal Lv Ejection Fraction Unknown status NCT01583881 Phase 2, Phase 3
20 Optimized Management of Comorbidity in Heart Failure With Preserved Ejection Fraction in the Elderly (>60 Years) (OPTIMIZE-HFPEF) Unknown status NCT02425371 Phase 3
21 A Multicenter, Randomized, Double-blind, Parallel Group, Active-controlled Study to Evaluate the Efficacy and Safety of LCZ696 Compared to Valsartan, on Morbidity and Mortality in Heart Failure Patients (NYHA Class II-IV) With Preserved Ejection Fraction (PARAGON-HF) Completed NCT01920711 Phase 3 LCZ696;Valsartan
22 Exercise Intolerance in Elderly Diastolic Heart Failure Completed NCT00123955 Phase 3 Spironolactone;Placebo
23 Phosphodiesterase-5 Inhibition to Improve Clinical Status and Exercise Capacity in Diastolic Heart Failure (RELAX) Completed NCT00763867 Phase 3 Placebo;Sildenafil
24 Evaluation of Enalapril Versus Placebo in Patients With Diastolic Heart Failure Completed NCT01411735 Phase 3 Enalapril;placebo
25 Effects of Sildenafil on Pulmonary Arterial Pressure in Patients With Heart Failure With Preserved Ejection Fraction ( HFpEF) and Pulmonary Hypertension Completed NCT01726049 Phase 3 Sildenafil;Placebo
26 Endothelin Receptor Blockade in Heart Failure With Diastolic Dysfunction and Pulmonary Hypertension Completed NCT00820352 Phase 3 bosentan;placebo
27 Pulmonary Hypertension Secondary to Heart Failure With Preserved Systolic Function: a Target of Phosphodiesterase - 5 Inhibition in a 1- Year Duration Study Completed NCT01156636 Phase 2, Phase 3 Sildenafil;Placebo
28 Interleukin-1 Blockade in Heart Failure With Preserved Ejection Fraction (HFpEF): a Randomized Placebo-controlled Double Blinded Study (D-HART2) Completed NCT02173548 Phase 2 Anakinra;Placebo
29 Randomised Double Blind Placebo Controlled Trial of Perhexiline in Heart Failure With Preserved Ejection Fraction Syndrome (HFpEF) Completed NCT00839228 Phase 2 Perhexiline;Placebo
30 A Randomized, Double-blind, Placebo-controlled Study of Ranolazine in Patients With Heart Failure With Preserved Ejection Fraction Completed NCT01163734 Phase 2 Ranolazine
31 A Phase 2 Randomised, Double-Blind, Placebo-Controlled Exploratory Efficacy Study Of Sitaxsentan Sodium To Improve Impaired Exercise Tolerance In Subjects With Diastolic Heart Failure Completed NCT00303498 Phase 2 Sitaxsentan sodium;Placebo
32 A Study of the Acute Hemodynamic and Myocardial Effects of Nesiritide in Diastolic Heart Failure. Completed NCT00309868 Phase 1, Phase 2 neseritide
33 Evaluation of Efficacy and Safety of Metoprolol XR in Patients Having Heart Failure With Normal Ejection Fraction: A Randomised, Double Blind,Placebo Controlled Trial Completed NCT03882710 Phase 2 Metoprolol XR
34 A Pilot Study Of ALT-711 In Elderly Patients With Isolated Diastolic Heart Failure: The DIAMOND Study Completed NCT00043836 Phase 2 ALT-711
35 Radiofrequency-based Speckle Tracking Echocardiography to Evaluate Diastolic Function Completed NCT01182805 Phase 1, Phase 2
36 A Dose Escalation Study to Evaluate the Effect of Inhaled Nitrite on Cardiopulmonary Hemodynamics in Subjects With Pulmonary Hypertension Completed NCT01431313 Phase 2 Inhaled Nitrite
37 Pharmacokinetics, Pharmacodynamics, and Impact of Inorganic Nitrate on Exercise in HFpEF Completed NCT02256345 Phase 2 KNO3;KCl
38 Stratified Treatment to Ameliorate Diastolic Left Ventricular Stiffness in Heart Failure With Preserved Ejection Fraction. A 35-week, Single-center, Prospective, Double-blind, Controlled, Randomized, 2x2 Crossover, Interventional Phase II Study, Investigating the Effect of Treatment With Dapagliflozin 10mg od on Left Ventricular Distensibility in Patients With Early HFpEF. Recruiting NCT04475042 Phase 2 Dapagliflozin;Placebo
39 Regress-HFPEF: Regression of Fibrosis & Reversal of Diastolic Dysfunction in HFPEF Patients Treated With Allogeneic CDCs Recruiting NCT02941705 Phase 2
40 Reducing Symptom Burden in Patients With Heart Failure With Preserved Ejection Fraction Using Ubiquinol and/or D-ribose Active, not recruiting NCT03133793 Phase 2 CoQ10;D-Ribose Oral Powder
41 A Randomized, Double-Blind, Placebo-Controlled, Multiple-Dose Study to Evaluate the Effects of Alagebrium on Exercise in Subjects With Diastolic Heart Failure Terminated NCT00662116 Phase 2 alagebrium;placebo
42 A Randomized Double-Blind, Placebo-Controlled, Multiple-Dose Study to Evaluate the Effects of Alagebrium on Exercise in Subjects With Diastolic Heart Failure Terminated NCT01913301 Phase 2 Alagebrium
43 Acute Hemodynamic Effects of Riociguat (BAY63-2521) in Patients With Pulmonary Hypertension Associated With Diastolic Heart Failure: A Randomized, Double-blind, Placebo-controlled, Single-dose Study in Three Ascending Dose Cohorts Terminated NCT01172756 Phase 2 Riociguat (BAY63-2521);Riociguat (BAY63-2521);Riociguat (BAY63-2521);Placebo
44 If Channel Blockade With Ivabradine in Patients With Diastolic Heart Failure Withdrawn NCT00757055 Phase 2 Ivabradine;Placebo
45 GRAPe Seed Extract and Ventriculovascular Investigation in Normal Ejection-Fraction Heart Failure Completed NCT01185067 Phase 1 grape seed extract (MegaNatural BP, Polyphenolics, Inc.)
46 Phase 1 Open Label, Dose Escalation Trial of Intracoronary Infusion of NAN-101 in Subjects With NYHA Class III Heart Failure Recruiting NCT04179643 Phase 1
47 Transcatheter Renal Denervation in Heart Failure With Normal Left Ventricular Ejection Fraction - a Safety and Efficacy Study of Irrigated Radiofrequency Catheter Unknown status NCT02115230
48 Markers of Oxidative Stress Present in Blood in Patients With Diastolic Dysfunction Unknown status NCT00846404
49 Diastolic Heart Failure Management by Nifedipine Unknown status NCT01157481 Conventional therapy plus nifedipine;Conventional therapy
50 Validation of New Non-Invasive Parameters of Diastolic Suction in the Left Ventricle Unknown status NCT02315859

Search NIH Clinical Center for Diastolic Heart Failure

Cochrane evidence based reviews: heart failure, diastolic

Sources

Genetic Tests for Diastolic Heart Failure

About this section
Sources

Anatomical Context for Diastolic Heart Failure

About this section

MalaCards organs/tissues related to Diastolic Heart Failure:

40
Heart, Kidney, Endothelial, Brain, Cardiac Myocytes, Eye, Neutrophil
Sources

Publications for Diastolic Heart Failure

About this section

Articles related to Diastolic Heart Failure:

(show top 50) (show all 1270)
# Title Authors PMID Year
1
Improvement of Shen'ge formula on heart function in diastolic heart failure: A protocol for randomized, double-blind, placebo-controlled clinical study. 61
33787645 2021
2
Use of Inflammatory Biomarkers and Real-Time Cardiac Catheterisation to Evaluate the Left Ventricular Diastolic Function in Patients With Diastolic Heart Failure. 61
32736962 2021
3
Diastolic Heart Failure: A Review of Current and Future Treatment Options. 61
32101908 2021
4
Frailty and Post-Hospitalization Outcomes in Patients with Heart Failure with Preserved Ejection Fraction. 61
33667443 2021
5
Neonatal hyperoxia inhibits proliferation and survival of atrial cardiomyocytes by suppressing fatty acid synthesis. 61
33507880 2021
6
Risk stratification with echocardiographic biomarkers in heart failure with preserved ejection fraction: the media echo score. 61
33656803 2021
7
The Effect of Echocardiography Based on Lipid Nano Contrast Agent on Cardiology Patients with Heart Failure and Atrial Fibrillation. 61
33183416 2021
8
Genetic Association Between Hypoplastic Left Heart Syndrome and Cardiomyopathies. 61
33325730 2021
9
Pericardiectomy for Constrictive Pericarditis: Analysis of Outcomes. 61
33722460 2021
10
Assessment of left-ventricular diastolic function in pediatric intensive-care patients: a review of parameters and indications compared with those for adults. 61
32506345 2021
11
Analysis of the results of patients treatment with metabolic syndrome, diabetic foot syndrome combined with diastolic dysfunction of the left ventricle. 61
33713090 2021
12
Cardiac Amyloid for the Internist. 61
33654598 2021
13
Seipin Deficiency Accelerates Heart Failure Due to Calcium Handling Abnormalities and Endoplasmic Reticulum Stress in Mice. 61
33778025 2021
14
A case report of coronary pulmonary artery fistula detected by transthoracic echocardiography in an elderly patient with dyspnea. 61
33623864 2021
15
Comparing outcomes of diabetic ketoacidosis hospitalisations in patients with diastolic heart failure: A retrospective propensity matched analysis of the nationwide inpatient sample. 61
33440066 2021
16
A case report of an infiltrative cardiomyopathy in everyday practice: a specific cause that cannot be missed in the elderly. 61
33442642 2020
17
Echocardiographic evaluation of left ventricular end diastolic pressure in patients with diastolic heart failure: A comparative study with real-time catheterization. 61
33285675 2020
18
Performance of Electronic Health Record Diagnosis Codes for Ambulatory Heart Failure Encounters. 61
32755626 2020
19
Nebivolol combined with tetrahydrobiopterin affects diastolic function in spontaneously hypertensive rats via the nitric oxide/cyclic guanosine monophosphate signalling pathway. 61
33267901 2020
20
Left atrial assist device function at various heart rates using a mock circulation loop. 61
33259242 2020
21
Cardiac Amyloidosis Detected on Imaging of Patients with Heart Failure. 61
33175723 2020
22
Cocaine, cardiomyopathy, and heart failure: a systematic review and meta-analysis. 61
33188223 2020
23
Bariatric Surgery and Hospitalization for Heart Failure in Morbidly Obese Patients. 61
32617916 2020
24
HOSPITAL Score, LACE Index and LACE+ Index as predictors of 30-day readmission in patients with heart failure. 61
31771947 2020
25
Neuregulins: protective and reparative growth factors in multiple forms of cardiovascular disease. 61
33063822 2020
26
Use of a Virtual Mock Loop model to evaluate a new left ventricular assist device for transapical insertion. 61
32089074 2020
27
The Effects of Preserving Mitral Valve Function on a Left Atrial Assist Device: An In Vitro Mock Circulation Loop Study. 61
32897890 2020
28
Echocardiographic reference ranges for normal cardiac Doppler data in healthy Turkish population: ECHO-DOP-TR Trial. 61
32815581 2020
29
Real-World Treatment Patterns, Healthcare Resource Utilization, and Costs for Patients with Newly Diagnosed Systolic versus Diastolic Heart Failure. 61
33343816 2020
30
Sex differences in circulating proteins in heart failure with preserved ejection fraction. 61
32831121 2020
31
Forensic interrogation of diabetic endothelitis in cardiovascular diseases and clinical translation in heart failure. 61
32879703 2020
32
Associations of Left Ventricular Structure and Function With Blood Pressure in Heart Failure With Preserved Ejection Fraction: Analysis of the TOPCAT Trial. 61
32750310 2020
33
The Unraveling: Cardiac and Musculoskeletal Defects and Their Role in Common Alzheimer Disease Morbidity and Mortality. 61
32407731 2020
34
Risk factors, resource use, and cost of postoperative low cardiac output syndrome. 61
32800368 2020
35
Outcomes of percutaneous mitral valve repair in systolic versus diastolic congestive heart failure. 61
32888837 2020
36
Kocuria kristinae pneumonia and bacteremia. 61
33100541 2020
37
Exercise and fluid challenge during right heart catheterisation for evaluation of dyspnoea. 61
32577217 2020
38
Clinical, Demographic, and Imaging Correlates of Anemia in Heart Failure With Preserved Ejection Fraction (from the RELAX Trial). 61
32307089 2020
39
Development of a Risk Score for Atrial Fibrillation in Adults With Diabetes Mellitus (from the ACCORD Study). 61
32291091 2020
40
Improved cardiac and venous pressures during hospital stay in patients with acute heart failure: an echocardiography and biomarkers study. 61
32277607 2020
41
Associations of adiponectin and leptin with brain natriuretic peptide in African Americans: the Jackson Heart Study. 61
32537565 2020
42
Constrictive Pericarditis: A Commonly Missed Cause of Treatable Diastolic Heart Failure. 61
32528763 2020
43
Diastolic Heart Failure in Patients With the Fontan Circulation: A Review. 61
32022823 2020
44
Comprehensive review of pericardial diseases using different imaging modalities. 61
32048125 2020
45
The utility of growth differentiation factor-15, galectin-3, and sST2 as biomarkers for the diagnosis of heart failure with preserved ejection fraction and compared to heart failure with reduced ejection fraction: a systematic review. 61
32472523 2020
46
Sickle cell disease: at the crossroads of pulmonary hypertension and diastolic heart failure. 61
31822569 2020
47
The Heart Failure with Preserved Ejection Fraction Conundrum-Redefining the Problem and Finding Common Ground? 61
32112345 2020
48
Gut microbiome of a porcine model of metabolic syndrome and HF-pEF. 61
32031871 2020
49
Acute Hemothorax Causing Hemorrhagic Shock Following Small-bore Thoracocentesis in a Patient on Clopidogrel: A Case Report and Literature Review. 61
32351811 2020
50
Enhanced clinical phenotyping by mechanistic bioprofiling in heart failure with preserved ejection fraction: insights from the MEDIA-DHF study (The Metabolic Road to Diastolic Heart Failure). 61
32063068 2020
Sources

Variations for Diastolic Heart Failure

About this section
Sources

Expression for Diastolic Heart Failure

About this section
Search GEO for disease gene expression data for Diastolic Heart Failure.
Sources

Pathways for Diastolic Heart Failure

About this section

Pathways related to Diastolic Heart Failure according to GeneCards Suite gene sharing:

(show all 26)
# Super pathways Score Top Affiliating Genes
1
Respiratory electron transport, ATP synthesis by chemiosmotic coupling, and heat production by uncoupling proteins. 65
Show member pathways
 13.03 TGFB1 REN NPPB NPPA NOS3 MMP9
2
p70S6K Signaling 63
Show member pathways
 12.96 TGFB1 REN CCN2 AGTR1 AGT ACE
3
Pathways in cancer 36
12.74 TGFB1 MMP9 MMP2 MMP1 AGTR1 AGT
4
Oxytocin signaling pathway 36
Show member pathways
 12.41 NPPB NPPA NOS3 AGTR1 AGT
5
cGMP-PKG signaling pathway 36
Show member pathways
 12.41 PDE5A NPPB NPPA NOS3 AGTR1 AGT
6
Dilated cardiomyopathy 36
Show member pathways
 12.14 TTN TGFB1 MYBPC3 AGT ACE
7
Colorectal Cancer Metastasis 63
12.1 TGFB1 MMP9 MMP2 MMP1
8
MicroRNAs in cardiomyocyte hypertrophy 1
Show member pathways
 12.07 TGFB1 NPPB NPPA AGT
9
Interleukin-4 and 13 signaling 65
11.88 TGFB1 MMP9 MMP2 MMP1
10
Matrix Metalloproteinases 1
Show member pathways
 11.8 MMP9 MMP2 MMP1
11
Angiogenesis (CST) 4
11.72 TGFB1 REN NOS3 MMP9 MMP2
12
Bladder cancer 36 1
11.66 MMP9 MMP2 MMP1
13
AGE/RAGE pathway 1
11.61 NOS3 MMP9 MMP2
14
Photodynamic therapy-induced NF-kB survival signaling 1
Show member pathways
 11.57 MMP9 MMP2 MMP1
15
Lung fibrosis 1
11.56 TGFB1 MMP9 MMP2 CCN2
16
Cell adhesion_ECM remodeling 23
11.55 MMP9 MMP2 MMP1
17
Renin secretion 36
11.49 REN NPPA AGTR1 AGT ACE
18
amb2 Integrin signaling 1
11.43 MMP9 MMP2 CCN2
19
AGE-RAGE signaling pathway in diabetic complications 36
11.43 TGFB1 NOS3 MMP2 CYBB AGTR1 AGT
20
Validated transcriptional targets of AP1 family members Fra1 and Fra2 1
11.24 NOS3 MMP9 MMP2 MMP1
21
A-beta Pathways: Uptake and Degradation 64
11.23 MMP9 MMP2 ACE
22
Plasma membrane estrogen receptor signaling 1
11.1 NOS3 MMP9 MMP2
23
Agents Acting on the Renin-Angiotensin System Pathway, Pharmacodynamics 60
Show member pathways
 11 TGFB1 REN NOS3 AGTR1 AGT ACE
24
A-beta Pathways: Plaque Formation and APP Metabolism 64
10.98 MMP9 MMP2 CST3 ACE
25
Syndecan-1-mediated signaling events 1
10.9 TGFB1 MMP9 MMP1
26
NO-dependent CFTR activation (normal and CF) 23
10.74 PDE5A NOS3
Sources

GO Terms for Diastolic Heart Failure

About this section

Cellular components related to Diastolic Heart Failure according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 9.85 TGFB1 REN NPPB NPPA MMP9 MMP2
2 extracellular matrix GO:0031012 9.65 TGFB1 MMP9 MMP2 MMP1 CCN2
3 collagen-containing extracellular matrix GO:0062023 9.43 TGFB1 NPPA MMP9 MMP2 CCN2 AGT
4 extracellular region GO:0005576 9.4 TTN TGFB1 REN NPPB NPPA MMP9

Biological processes related to Diastolic Heart Failure according to GeneCards Suite gene sharing:

(show all 40)
# Name GO ID Score Top Affiliating Genes
1 cellular protein metabolic process GO:0044267 9.94 NPPA MMP2 MMP1 CST3
2 kidney development GO:0001822 9.88 REN AGTR1 AGT ACE
3 female pregnancy GO:0007565 9.85 TGFB1 NPPA AGT
4 negative regulation of cell growth GO:0030308 9.85 TGFB1 NPPB NPPA AGT
5 extracellular matrix disassembly GO:0022617 9.8 MMP9 MMP2 MMP1
6 positive regulation of blood vessel endothelial cell migration GO:0043536 9.79 TGFB1 NOS3 MIR499A
7 positive regulation of protein secretion GO:0050714 9.77 TTN TGFB1 ANKRD1
8 collagen catabolic process GO:0030574 9.77 MMP9 MMP2 MMP1
9 blood vessel remodeling GO:0001974 9.74 NOS3 AGT ACE
10 cellular response to mechanical stimulus GO:0071260 9.73 TGFB1 NPPA ANKRD1 AGT
11 aortic valve morphogenesis GO:0003180 9.71 TGFB1 NPPA NOS3
12 response to amyloid-beta GO:1904645 9.68 MMP9 MMP2
13 amyloid-beta metabolic process GO:0050435 9.68 REN ACE
14 positive regulation of renal sodium excretion GO:0035815 9.68 NPPB AGT
15 negative regulation of systemic arterial blood pressure GO:0003085 9.67 NPPB NPPA
16 positive regulation of cardiac muscle cell differentiation GO:2000727 9.67 TGFB1 MIR499A
17 angiotensin maturation GO:0002003 9.66 REN ACE
18 cardiac muscle tissue morphogenesis GO:0055008 9.66 TTN ANKRD1
19 cGMP biosynthetic process GO:0006182 9.65 NPPB NPPA
20 positive regulation of cardiac muscle contraction GO:0060452 9.65 NPPA CCN2
21 receptor guanylyl cyclase signaling pathway GO:0007168 9.65 NPPB NPPA
22 vasodilation GO:0042311 9.65 NPPA NOS3 AGT
23 negative regulation of biomineral tissue development GO:0070168 9.64 TGFB1 NOS3
24 positive regulation of cholesterol esterification GO:0010873 9.63 AGTR1 AGT
25 regulation of vasoconstriction GO:0019229 9.63 AGTR1 AGT ACE
26 positive regulation of NAD(P)H oxidase activity GO:0033864 9.62 AGTR1 AGT
27 positive regulation of vascular smooth muscle cell proliferation GO:1904707 9.62 MMP9 MMP2 MIR499A AGT
28 connective tissue development GO:0061448 9.61 TGFB1 CCN2
29 negative regulation of extracellular matrix disassembly GO:0010716 9.61 TGFB1 CST3
30 regulation of renal sodium excretion GO:0035813 9.58 AGTR1 AGT
31 positive regulation of cellular protein metabolic process GO:0032270 9.58 TGFB1 AGTR1 AGT
32 regulation of blood vessel diameter by renin-angiotensin GO:0002034 9.56 AGTR1 AGT
33 cellular response to UV-A GO:0071492 9.54 MMP9 MMP2 MMP1
34 mononuclear cell proliferation GO:0032943 9.52 TGFB1 ACE
35 regulation of renal output by angiotensin GO:0002019 9.51 AGT ACE
36 regulation of blood volume by renin-angiotensin GO:0002016 9.49 REN AGT
37 regulation of systemic arterial blood pressure by renin-angiotensin GO:0003081 9.43 AGTR1 AGT ACE
38 renin-angiotensin regulation of aldosterone production GO:0002018 9.33 REN AGTR1 AGT
39 regulation of blood vessel diameter GO:0097746 9.26 NPPB NOS3 AGTR1 ACE
40 regulation of blood pressure GO:0008217 9.1 REN NPPB NPPA NOS3 AGT ACE

Molecular functions related to Diastolic Heart Failure according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 peptidase activity GO:0008233 9.72 REN MMP9 MMP2 MMP1 ACE
2 metallopeptidase activity GO:0008237 9.46 MMP9 MMP2 MMP1 ACE
3 titin binding GO:0031432 9.37 MYBPC3 ANKRD1
4 hormone receptor binding GO:0051427 9.26 NPPB NPPA
5 endopeptidase activity GO:0004175 9.02 REN MMP9 MMP2 MMP1 ACE
6 bradykinin receptor binding GO:0031711 8.96 AGTR1 ACE
Sources

Sources for Diastolic Heart Failure

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 20-May-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 Tocris
70 UMLS
71 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....